Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0002-9149(88)91329-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of chitosan/diosgenin-infused manganese dioxide nanocomposite for highly effective photocatalytic and antibacterial activity.
Int J Biol Macromol
December 2024
Department of Biotechnology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai 602105, Tamil Nadu, India.
The efficacy of the nanocomposite of manganese dioxide and diosgenin-incorporated chitosan (MnO/Dio@CS) was assessed by studying the photodegradation of two organic dyes, Acid Green (AG) and Malachite Green Oxalate (MGO), under visible light irradiation. The synthesized MnO/Dio@CS nanocomposites were characterized by Field Emission Scanning Electron Microscopy (FESEM), High-Resolution Transmission Electron Microscopy (HRTEM), Fourier Transform Infrared Spectroscopy (FTIR), X-ray diffraction (XRD), UV-vis spectroscopy. The MnO/Dio@CS nanocomposites exhibited exceptional photocatalytic efficacy, prolonged durability, and quick degradation of the dye solution to 87.
View Article and Find Full Text PDFMultifunctional aluminum alloy slippery liquid-infused surface with porous and boehmite nanoflower structure.
J Colloid Interface Sci
December 2024
Ministry of Education Key Laboratory for the Green Preparation and Application of Functional Materials, Hubei University, Wuhan 430062, People's Republic of China; State Key Laboratory of Solid Lubrication, Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences, Lanzhou 730000, People's Republic of China. Electronic address:
The depletion of lubricants in (slippery liquid-infused porous surfaces) SLIPS poses a significant challenge to their long-term functionality. While line-shaped rough structures can mitigate lubricant loss to some extent, they often fail to provide the stability required for sustained performance. In this study, we present a novel porous nanoflower aluminum alloy slippery liquid-infused surface (P-NF-AA SLIPS), which integrates a porous framework with a rough nanoflower structure.
View Article and Find Full Text PDFAcute Intermittent Porphyria in an Adolescent Patient: Diagnostic and Treatment Challenges.
Cureus
November 2024
Internal Medicine-Pediatrics, University of California Los Angeles, Los Angeles, USA.
Acute intermittent porphyria (AIP) is a rare inherited metabolic disorder caused by decreased activity of the enzyme porphobilinogen deaminase in the heme synthesis pathway. This leads to the accumulation of toxic porphyrin precursors, such as porphobilinogen and δ-aminolevulinic acid. Clinical manifestations typically include episodic bouts of severe neurovisceral pain and autonomic dysfunction.
View Article and Find Full Text PDFLandscape of transarterial chemoembolization represented interventional therapy for hepatocellular carcinoma.
World J Gastrointest Surg
December 2024
Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China.
This article discusses the article written by Tan . Transarterial chemoembolization (TACE) is one of the main treatment methods for advanced hepatocellular carcinoma (HCC). There are other vascular interventional therapies, including drug-eluting bead TACE, transarterial radioembolization, and hepatic arterial infusion chemotherapy.
View Article and Find Full Text PDFVancomycin administration and AUC/MIC in patients with acute kidney injury on hemodialysis (HD): randomized clinical trial.
Sci Rep
December 2024
Internal Medicine Department - Nephrology, Botucatu School of Medicine, University São Paulo State-UNESP, District of Rubiao Junior, Botucatu, Sao Paulo, Brazil.
The pharmacokinetics and pharmacodynamics (PK/PD) of vancomycin change during HD, increasing the risk of subtherapeutic concentrations. The aim of this study was to evaluate during and after the conventional and prolonged hemodialysis sessions to identify the possible risk of the patient remaining without adequate antimicrobial coverage during therapy. Randomized, non-blind clinical trial, including critically ill adults with septic AKI on conventional (4 h) and prolonged HD (6 and 10 h) and using vancomycin for at least 72 h.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!